Advertisement

Predictors of conversion to sinus rhythm using ibutilide for atrial fibrillation or flutter

      Ibutilide is a new class III intravenous antiarrhythmic agent approved for rapidly converting atrial fibrillation (AF) or flutter (AFl) to sinus rhythm. Several studies have documented ibutilide’s efficacy in terminating these arrhythmias or enhancing their nonpharmacologic conversion. The conversion rate varies between 34% and 58%.
      • Abi-Mansour P.
      • Carberry P.A.
      • McCowan R.J.
      • Henthorn R.W.
      • Dunn G.H.
      • Perry K.T.
      Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation.
      ,
      • Stambler B.S.
      • Wood M.A.
      • Ellenbogen K.A.
      • Perry K.T.
      • Wakefield L.K.
      • VanderLugt J.T.
      Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation.
      ,
      • Ellenbogen K.A.
      • Stambler B.S.
      • Wood M.A.
      • Sager P.T.
      • Wesley Jr, R.C.
      • Meissner M.C.
      • Zoble R.G.
      • Wakefield L.K.
      • Perry K.T.
      • Vanderlugt J.T.
      Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter a dose-response study.
      ,
      • Stambler B.S.
      • Wood M.A.
      • Ellenogen K.A.
      Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing.
      Some subgroups, such as patients with AFl, have a higher conversion rate (63% to 76%). Identification of groups most likely to respond to treatment is important for optimal use of available resources. The goal of this retrospective study was to determine what clinical and electrocardiographic factors can predict conversion in response to ibutilide treatment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Abi-Mansour P.
        • Carberry P.A.
        • McCowan R.J.
        • Henthorn R.W.
        • Dunn G.H.
        • Perry K.T.
        Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation.
        Am Heart J. 1998; 136: 632-642
        • Stambler B.S.
        • Wood M.A.
        • Ellenbogen K.A.
        • Perry K.T.
        • Wakefield L.K.
        • VanderLugt J.T.
        Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation.
        Circulation. 1996; 94: 1613-1621
        • Ellenbogen K.A.
        • Stambler B.S.
        • Wood M.A.
        • Sager P.T.
        • Wesley Jr, R.C.
        • Meissner M.C.
        • Zoble R.G.
        • Wakefield L.K.
        • Perry K.T.
        • Vanderlugt J.T.
        Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter.
        J Am Coll Cardiol. 1996; 28: 130-136
        • Stambler B.S.
        • Wood M.A.
        • Ellenogen K.A.
        Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing.
        Am J Cardiol. 1996; 77: 960-966
        • Mattioni T.
        • Denker S.
        • Riggio D.
        • Smith J.
        • Welch S.
        • Perry K.
        • Wakefield L.
        • Vanderlugt J.
        Efficacy and safety of intravenous ibutilide in the treatment of atrial flutter and atrial fibrillation following valvular or coronary artery bypass surgery.
        PACE. 1997; 20 (abstr): 1059
        • Fozzard H.
        • Sheets M.
        Cellular mechanism of action of cardiac glycosides.
        J Am Coll Cardiol. 1985; 5: 10A-15A
        • Rosen M.R.
        Cellular electrophysiology of digitalis toxicity.
        J Am Coll Cardiol. 1985; 5: 22A-34A
        • Lee K.S.
        Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells.
        J Pharmacol Exp Ther. 1992; 262: 99-108
        • Yang T.
        • Snyders D.J.
        • Roden D.M.
        Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects.
        Circulation. 1995; 91: 1799-1806